Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Published on 08/10/202508/10/2025 by Medical Lab Scientist

Prof. Ding Wen Wu | Transfusion Medicine | Best Researcher Award

Professor | NYU Grossman School of Medicine | United states

Prof. Ding Wen Wu is a distinguished researcher and educator in the field of transfusion medicine, currently affiliated with the NYU Grossman School of Medicine, United States. With a career dedicated to advancing patient blood management and diagnostic innovation, he has made notable contributions that bridge laboratory research and real-world clinical practice. His research focuses on improving transfusion safety, optimizing resource utilization, and promoting evidence-based approaches that enhance healthcare efficiency and patient outcomes. Prof. Wu’s academic profile demonstrates strong scholarly impact, with 10 published scientific documents, 97 citations, and an h-index of 3, reflecting the quality and growing influence of his work within the international medical community. His studies have appeared in highly respected journals such as JAMA Internal Medicine, Life, Healthcare, and the Journal of Clinical Apheresis, where his findings have shaped new perspectives in transfusion medicine and clinical diagnostics. Beyond research, Prof. Wu is also recognized for his mentorship and leadership in education, actively guiding emerging medical scientists and fostering collaboration, innovation, and integrity in research. His interdisciplinary approach and commitment to continuous improvement underscore his vision for integrating artificial intelligence, real-world data analytics, and precision-based methodologies into modern healthcare systems. Through his dedication to advancing transfusion science and promoting global standards in laboratory medicine, Prof. Ding Wen Wu continues to serve as an inspiring figure whose work contributes significantly to safer, more efficient, and patient-centered medical practices worldwide.

Profiles: Scopus | ORCID

Feaured Publications

1. Wu, D. W., Friedman, M. T., Lombardi, D. P., Hwang, R., Sender, J., Cobaj, V., Karpinos, R. (2024). Impact of patient blood management on red blood cell utilization in an urban community teaching hospital: A seven-year retrospective study. Life, 14(2), 232.

2. Karpinos, R., Friedman, M., Lombardi, D., Li, Y., Cobaj, V., Niazi, M., Lai, P., & Wu, D. W. (2025). Implementation and impact of a patient blood management program in an urban community hospital: An eight-year study. Healthcare, 13(19), 2462.

3. Tanhehco, Y. C., Alsammak, M., Wu, D. W., Costa, V., Chhibber, V., Levenbrown, Y., … Wehrli, G. (2024). An annual review of important apheresis articles from the American Society for Apheresis Attending Physician Subcommittee. Journal of Clinical Apheresis, 39(6), e22152.

4. Wu, D. W., Jacobson, J., Lifshitz, M., Li, Y., Lyu, C., Friedmann, R., … Hilbert, T. (2023). Association between post-transfusion hemoglobin S levels and pre-transfusion levels at the next scheduled transfusion. Journal of Clinical Apheresis, 38(5), 529–539.

5. Ortigoza, M. B., Yoon, H., Goldfeld, K. S., Troxel, A. B., Daily, J. P., Wu, Y., … Wu, D. W. (2022). Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: A randomized clinical trial. JAMA Internal Medicine, 182(2), 115–126.

Liying Ren | Molecular Biology | Best Researcher Award

Published on 13/09/202513/09/2025 by Medical Lab Scientist

Dr. Liying Ren | Molecular Biology | Best Researcher Award

Liying Ren | Peking University |China

Ren Liying is a medical researcher in hepatology and oncology, currently pursuing her Ph.D. in Internal Medicine at the Peking University Hepatology Institute, Peking University People’s Hospital, under the mentorship of Professor Chen Hongsong. She earned her Bachelor’s degree in Clinical Medicine from Hubei University of Science and Technology and her Master’s degree from Guilin Medical University under Professor Liao Weijia, before advancing to doctoral studies. Her research focuses on hepatocellular carcinoma (HCC), with an emphasis on integrating molecular biology, imaging, and clinical practice to improve patient outcomes. Ren has authored and co-authored several impactful publications in respected journals, including Cancers, Journal of Hepatocellular Carcinoma, BMC Cancer, World Journal of Gastroenterology, and Cancer Medicine. As first author, her study in Cancers identified the tumor-suppressive role of hemopexin in HCC via TNF-α–mediated mitochondrial apoptosis, while her review explored radiomics and radiogenomics as tools to bridge imaging and molecular characterization in liver cancer. She has also contributed to predictive models and radiomics-based approaches for recurrence and prognosis stratification after surgical resection of HCC. With a strong clinical foundation and commitment to translational research, Ren represents a new generation of physician-scientists advancing precision medicine in liver disease and cancer.

profile: Google scholar

Featured Publications

1.Ren L#, Man Y#, Zhang X, Guo Q, She S, Yang Y, Fei R, Cong X, Chen D, Wei W, Chen H*.**
Hemopexin Suppresses Hepatocellular Carcinoma via TNF-α-Mediated Mitochondrial Apoptosis.
Cancers. 2025; 17(18):2969. (Q2, IF=4.4)

2.Ren L#, Chen DB#, Yan X, She S, Yang Y, Zhang X, Liao W, Chen H.**
Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2024; 11:2359-2372. (Q2, IF=3.4)

3.Ren L#, Chen D#, Xu W, Xu T, Wei R, Suo L, Huang Y, Chen H, Liao W.**
Predictive Potential of Nomogram Based on GMWG for Patients with Hepatocellular Carcinoma after Radical Resection. BMC Cancer. 2021; 21(1):817. (Q2, IF=3.4)

4.Li S#, Su L#, Xu T#, Ren L#, et al.
Radiomics Model Based on Contrast-Enhanced CT to Predict Early Recurrence in Patients with Hepatocellular Carcinoma after Radical Resection. World Journal of Gastroenterology. 2023; 29(26):4186-4199. (Q1, IF=5.1)

5.Xu T#, Ren L#, Liao M#, Zhao B, Wei R, Zhou Z, He Y, Zhang H, Chen D, Chen H, Liao W.**
Preoperative Radiomics Analysis of Contrast-Enhanced CT for Microvascular Invasion and Prognosis Stratification in Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2022; 9:189-201. (Q2, IF=3.4)

6.Chen D#, Gao J#, Ren L#, Chen P, Yang Y, She S, Xie Y, Liao W, Chen H.*
A Signature Based on NKG2D Ligands to Predict the Recurrence of Hepatocellular Carcinoma after Radical Resection.
Cancer Medicine. 2023; 12(5):6337-6347. (Q2, IF=3.1)

Irene Gómez | Molecular Biology | Best Researcher Award

Published on 15/04/202515/04/2025 by Medical Lab Scientist

Dr. Irene Gómez | Molecular Biology | Best Researcher Award

Investigador Postdoctoral at Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Spain

Irene Gómez Delgado is a passionate and highly skilled postdoctoral researcher working at the Health Research Foundation of Clínico San Carlos Hospital, where she specializes in biomedicine, medical microbiology, and environmental risks. She has shown exceptional dedication to scientific discovery, focusing on the genetic and molecular basis of complex diseases, particularly in the area of immunology and nephrology. Irene’s collaborative spirit, commitment to rigorous methodology, and enthusiasm for public science engagement have marked her as an emerging leader in her field.

profile

orcid

Education

Irene Gómez Delgado’s academic journey reflects both excellence and depth, beginning with her Bachelor’s Degree in Biology from Universidad Complutense de Madrid, earned in 2016. She continued her academic pursuit with a Master’s Degree in Immunology Research from the same university in 2017, equipping her with advanced knowledge of immune system mechanisms. She culminated her formal education by earning a PhD in Molecular Bioscience at Universidad Autónoma de Madrid in 2022, where she developed a strong foundation in molecular biology, genetic research, and experimental design, all of which continue to influence her contributions to biomedical science.

Experience

Irene has steadily advanced her scientific career through key research roles, beginning as a predoctoral researcher at the Health Research Foundation of La Paz University Hospital from 2017 to 2022, where she gained comprehensive experience in molecular biology, laboratory supervision, and project execution. Since 2022, she has been working as a postdoctoral researcher at Clínico San Carlos Hospital’s Laboratory of Genetic and Molecular Basis of Complex Diseases. Alongside her research, Irene has co-directed Master’s Final Projects and supervised undergraduate students and laboratory technicians, showing strong leadership and mentorship capabilities.

Research Interest

Irene’s research interests lie primarily in understanding the molecular and genetic mechanisms underlying immunological and nephrological diseases. Her scientific focus includes studying complement system dysregulation, genetic variants related to immune system proteins, and mitochondrial alterations in immune cells. Her work also extends to infectious disease complications, including severe COVID-19 immune responses, making her research impactful for both rare disease understanding and global health challenges.

Award

Irene Gómez Delgado has been recognized for her scientific achievements through multiple awards. In 2023, she was honored with the Extraordinary Doctorate Award by Universidad Autónoma de Madrid, celebrating the outstanding quality and impact of her doctoral work. She also received the Poster Communication Award from the European Complement Network in 2022 for her contribution at the 18th European Meeting on Complement in Human Disease held in Bern, Switzerland. These awards highlight her scientific excellence and growing reputation in the immunology and nephrology research communities.

Publication

Dr. Gómez Delgado has co-authored several peer-reviewed scientific articles that contribute to the advancement of biomedical research.

Long term mitochondrial and metabolic impairment in lymphocytes of subjects who recovered after severe COVID-19 — published in 2025 in Cell Biology and Toxicology.

Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production — published in 2024 in International Journal of Molecular Sciences.

Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome — published in 2021 in Frontiers in Immunology.

Low factor H-related 5 levels contribute to infection-triggered haemolytic uraemic syndrome and membranoproliferative glomerulonephritis — published in 2021 in Clinical Kidney Journal.

High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B — published in 2018 in Frontiers in Immunology.

Contribution of functional and quantitative genetic variants of Complement Factor H and Factor H-Related (FHR) proteins on renal pathology — published in 2022 in Nefrología.

Altered expression of FHR-1 and FHR-2 glycoforms in IgA nephropathy patients — published in 2024 in European Journal of Immunology (Meeting Abstract).

Conclusion

Dr. Irene Gómez Delgado exemplifies the qualities of a leading researcher through her pioneering contributions to immunology and molecular medicine, her active engagement in scientific dissemination, and her commitment to mentorship and collaborative research. Her career trajectory reflects an unwavering pursuit of knowledge and societal impact, which makes her a deserving and inspiring nominee for the Research for Best Researcher Award.